Founded by European biotech entrepreneur Sir Christoper Evans, Celsis was floated on the London Stock Exchange with the dedicated focus on rapid microbial detection technology in 1993. Since its inception, Celsis International plc has grown from its once small headquarters in England to include offices in the US, the Netherlands, France, Germany and Belgium as well as a global network of distributors.
Celsis' purchase of Lumac, from Perstorp Analytical in 1996, and ConCell in 2001 has allowed Celsis to augment its organic development and made it the leading provider of rapid diagnostic and microbial monitoring systems and analytical services in the world.
Celsis has a unique scientific skill base of biochemists, enzymologists and microbiologists as well as an experienced international management team. This combination of R&D, commercial skills and ongoing technical support produces an in-depth understanding of the need for rapid testing methods in the consumer product manufacturing environment.

http://www.celsis.com

Celsis International plc, the international life sciences products and laboratory services company, today announces its preliminary results for the year ended 31 March 2009. 
 

Financial Highlights

<!--[if !supportLists]-->·         <!--[endif]-->Group revenues sustained at $52.5 million despite challenging market conditions (2008: $52.9 million)

<!--[if !supportLists]-->·         <!--[endif]-->Operating profit increased 17.9% to $13.2 million (2008: $11.2 million)

<!--[if !supportLists]-->·         <!--[endif]-->EBITDA increased 13.9% to $15.6 million (2008: $13.7 million) and EBITDA margin increased to 29.7% (2008: 25.9%)

<!--[if !supportLists]-->·         <!--[endif]-->Profit before tax increased 21.9% to $12.8 million (2008: $10.5 million) and profit before tax and amortisation increased 19.6% to $13.4 million (2008: $11.2 million)

<!--[if !supportLists]-->·         <!--[endif]-->Group cash inflows increased to $13.7 million (2008: $12.9 million)

<!--[if !supportLists]-->·         <!--[endif]-->Earnings per share (EPS) increased 27.8% to 41.88 cents (2008: 32.78 cents) and EPS adjusted for amortisation of intangible assets increased 25.1% to 44.57 cents per share (2008: 35.62 cents per share)

<!--[if !supportLists]-->·         <!--[endif]-->All numbers above reflect continuing operations and all comparative 2008 numbers have been restated to reflect the prior year results of continuing operations
 
 

Operational Highlights

<!--[if !supportLists]-->·         <!--[endif]-->Rapid Detection revenues increased 9.2% to $23.7 million (2008: $21.7 million) 

<!--[if !supportLists]-->-         <!--[endif]-->Strong consumable reagent sales and healthy growth in instrument placements 

<!--[if !supportLists]-->-         <!--[endif]-->Successful launch of Celsis ReACT™ RNA-based assay 

<!--[if !supportLists]-->·         <!--[endif]-->Analytical Services revenues decreased 4.7% to $18.1 million (2008: $19.0 million) 

<!--[if !supportLists]-->-         <!--[endif]-->Strong recovery in H2 after 9.2% fall in H1 on continuing operations

<!--[if !supportLists]-->-         <!--[endif]-->Discontinuation of Development Services business unit significantly improves profit margins

<!--[if !supportLists]-->·         <!--[endif]-->In Vitro Technologies revenues decreased 13.0% to $10.7 million (2008: $12.3 million)

<!--[if !supportLists]-->-         <!--[endif]-->Pharmaceutical industry consolidations impacted H2

<!--[if !supportLists]-->-         <!--[endif]-->Exclusive alliance established with leading life sciences company Promega